Summary:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 600 mg Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects
Qualified Participants Must:
• Men and women 18 to 79 years of age
May be on statin therapy or lipid-altering medications.
Fasting triglycerides levels between 500 and 1500 mg/dL.
Qualified Participants May Receive:
Study Medication and Care at no cost.
Compensation for time and travel.